Intra-Cellular TherapiesITCI
About: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Employees: 561
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
76% more call options, than puts
Call options by funds: $29.3M | Put options by funds: $16.6M
43% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 10 (+3) [Q3]
6% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 125
4% more capital invested
Capital invested by funds: $6.95B [Q2] → $7.26B (+$311M) [Q3]
2.35% less ownership
Funds ownership: 96.11% [Q2] → 93.75% (-2.35%) [Q3]
6% less funds holding
Funds holding: 370 [Q2] → 348 (-22) [Q3]
31% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 62
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Needham Ami Fadia 34% 1-year accuracy 56 / 166 met price target | 21%downside $100 | Hold Downgraded | 13 Jan 2025 |
JP Morgan Jessica Fye 39% 1-year accuracy 15 / 38 met price target | 30%downside $89 | Overweight Maintained | 4 Nov 2024 |
Financial journalist opinion
Based on 13 articles about ITCI published over the past 30 days
